INDUSTRY UPDATES
Peptide Industry News
New research, regulatory developments, and compound updates. No fluff, no opinion pieces masquerading as news.
Semaglutide Compounding Safety Update: FDA Concerns and Documentation Risks
FDA has warned about compounded semaglutide dosing errors, salt forms, and unapproved GLP-1 marketing. Here is the research-facing context.
Allison Dietiker, Ph.D.
Tirzepatide Shortage and Compounding Policy: 2026 FDA Update
Tirzepatide policy has shifted from shortage-era flexibility to a tighter regulatory environment. Researchers should separate mechanism from supply claims.
FDA GLP-1 Compounding Update: What Researchers Should Know in 2026
FDA scrutiny of unapproved GLP-1 products, compounding policy, shortage status, and 503B bulk-substance rules is reshaping the 2026 incretin research landscape.
DEEP DIVES
Research Hub
175+ research articles with mechanisms, PubMed references, and COA analysis.
GUIDES
Research Blog
Buying guides, company comparisons, and peptide education for serious researchers.
CATALOG
Research Compounds
All compounds third-party tested with batch-specific COA. US-based fulfillment.